SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:55480e09-2879-42df-8bc8-1403435b9c02"
 

Search: onr:"swepub:oai:lup.lub.lu.se:55480e09-2879-42df-8bc8-1403435b9c02" > EULAR points to con...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Gordon, C. (author)

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • 2008-04-03
  • BMJ,2009

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:55480e09-2879-42df-8bc8-1403435b9c02
  • https://lup.lub.lu.se/record/1405049URI
  • https://doi.org/10.1136/ard.2007.083022DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:118411041URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objective: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by relapses and remissions. Designing a high-quality randomised controlled trial poses many challenges. We have developed evidenced-based recommendations for points to consider in conducting clinical trials in patients with SLE. Methods: The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Initially, the evidence for clinical trial end-points in SLE was evaluated and this has been reported separately. A consensus approach was developed by the SLE Task Force in formulating recommendations for points to consider when conducting clinical trials in SLE. Results: The literature review revealed that most outcome measures used in phase 2/3 trials in SLE have not actually been validated in clinical trials, although other forms of validation have been undertaken. The final recommendations for points to consider for conducting clinical trials in SLE address the following areas: study design, eligibility criteria, outcome measures including adverse events, concomitant therapies for SLE and its complications. Conclusions: Recommendations for points to consider when conducting clinical trials in SLE were developed using an evidence-based approach followed by expert consensus. The recommendations should be disseminated, implemented and then reviewed in detail and revised using an evidence-based approach in about 5 years, by which time there will be further evidence to consider from current clinical trials.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bertsias, G. (author)
  • Ioannidis, J. P. A. (author)
  • Boletis, J. (author)
  • Bombardieri, S. (author)
  • Cervera, R. (author)
  • Dostal, C. (author)
  • Font, J. (author)
  • Gilboe, I-M (author)
  • Houssiau, F. (author)
  • Huizinga, T. W. J. (author)
  • Isenberg, D. (author)
  • Kallenberg, C. G. M. (author)
  • Khamashta, M. A. (author)
  • Piette, J-C (author)
  • Schneider, M. (author)
  • Smolen, J. S. (author)
  • Sturfelt, GunnarLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)reum-gst (author)
  • Tincani, A. (author)
  • Van Vollenhoven, R.Karolinska Institutet (author)
  • Boumpas, D. T. (author)
  • Reumatologi och molekylär skelettbiologiSektion III (creator_code:org_t)

Related titles

  • In:Annals of the Rheumatic Diseases: BMJ68:4, s. 470-4761468-20600003-4967

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view